BRPI0409413A - composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável - Google Patents

composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável

Info

Publication number
BRPI0409413A
BRPI0409413A BRPI0409413-1A BRPI0409413A BRPI0409413A BR PI0409413 A BRPI0409413 A BR PI0409413A BR PI0409413 A BRPI0409413 A BR PI0409413A BR PI0409413 A BRPI0409413 A BR PI0409413A
Authority
BR
Brazil
Prior art keywords
salt
pharmaceutical composition
absorption
treating
methods
Prior art date
Application number
BRPI0409413-1A
Other languages
English (en)
Inventor
Roger R C New
Original Assignee
Axcess Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcess Ltd filed Critical Axcess Ltd
Publication of BRPI0409413A publication Critical patent/BRPI0409413A/pt
Publication of BRPI0409413B1 publication Critical patent/BRPI0409413B1/pt
Publication of BRPI0409413B8 publication Critical patent/BRPI0409413B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, USO DE UM áCIDO OU SAL BILIAR NãO CONJUGADO, E, MéTODOS PARA INTENSIFICAR A ABSORçãO DE UM PRINCìPIO MACROMOLECULAR ATIVO EM UM PACIENTE E PARA TRATAR UM PACIENTE QUE ESTEJA SOFRENDO DE UMA CONDIçãO OU DOENçA TRATáVEL". A invenção refere-se a uma composição farmacêutica compreendendo uma mistura de: (a) um princípio macromolecular ativo; e (b) um sal ou ácido biliar não conjugado; e um aditivo escolhido dentre galato de propila, butil hidróxi anisol (BHA) e seus análogos e derivados, ou misturas destes.
BRPI0409413A 2003-04-15 2004-04-15 composição farmacêutica, e, uso de um ácido ou sal biliar não conjugado BRPI0409413B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308734.3A GB0308734D0 (en) 2003-04-15 2003-04-15 Uptake of macromolecules
PCT/GB2004/001651 WO2004091667A1 (en) 2003-04-15 2004-04-15 Uptake of macromolecules

Publications (3)

Publication Number Publication Date
BRPI0409413A true BRPI0409413A (pt) 2006-04-25
BRPI0409413B1 BRPI0409413B1 (pt) 2017-05-02
BRPI0409413B8 BRPI0409413B8 (pt) 2021-05-25

Family

ID=9956848

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409413A BRPI0409413B8 (pt) 2003-04-15 2004-04-15 composição farmacêutica, e, uso de um ácido ou sal biliar não conjugado

Country Status (20)

Country Link
US (1) US8314058B2 (pt)
EP (1) EP1613355B1 (pt)
JP (1) JP5047611B2 (pt)
KR (1) KR101135784B1 (pt)
CN (1) CN100506280C (pt)
AU (1) AU2004229217B2 (pt)
BR (1) BRPI0409413B8 (pt)
CA (1) CA2522146C (pt)
CY (1) CY1113461T1 (pt)
DK (1) DK1613355T3 (pt)
ES (1) ES2394640T3 (pt)
GB (1) GB0308734D0 (pt)
HK (1) HK1078277A1 (pt)
NZ (1) NZ543172A (pt)
PL (1) PL1613355T3 (pt)
PT (1) PT1613355E (pt)
RU (1) RU2349344C2 (pt)
SI (1) SI1613355T1 (pt)
WO (1) WO2004091667A1 (pt)
ZA (1) ZA200508344B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
WO2008132731A2 (en) * 2007-04-26 2008-11-06 Oramed Pharmaceuticals, Inc Methods and compositions for rectal administration of insulin
EP3741359A1 (en) 2008-08-18 2020-11-25 Entera Bio Ltd. Methods and compositions for oral administration of proteins
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
DK3677252T3 (da) 2012-03-19 2023-10-02 Cidara Therapeutics Inc Doseringsregimer for echinocandin-klasse forbindelser
CA2888302C (en) 2012-10-17 2016-05-31 Methylation Sciences International Srl Compositions comprising s-adenosylmethionine and a gallic acid ester
AU2018360382A1 (en) 2017-10-31 2020-06-18 Medimmune Limited Oral delivery of GLP-1 peptide analogs
US20230109708A1 (en) * 2020-01-23 2023-04-13 Axcess (UK) Ltd Cellular Uptake
CN116916908A (zh) * 2021-01-22 2023-10-20 爱克赛斯(英国)有限公司 用于保持治疗化合物完整性的edta和egta
GB2625490A (en) * 2021-01-27 2024-06-19 D&D Pharmatech Inc Pharmaceutical composition comprising large physiologically active substance and excipient
WO2023038450A1 (ko) * 2021-09-07 2023-03-16 (주)디앤디파마텍 거대 생리활성 물질 및 부형제를 포함하는 약학 조성물
KR102412437B1 (ko) 2022-03-10 2022-06-23 주식회사 보은기계 선택적 시공이 가능한 수로시스템

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB354184A (en) 1929-04-30 1931-07-29 Pharmagans Pharmaceutisches In An improved process for the production of hormone preparations
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
JPS5257313A (en) 1975-11-07 1977-05-11 Yamanouchi Pharmaceut Co Ltd Manufacture of micellar insuline emulsion preparations
JPS56138168A (en) * 1980-03-31 1981-10-28 Teijin Ltd Movel active vitamin d3 derivative composition
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IT1251685B (it) 1991-10-11 1995-05-19 Isf Spa Composizioni farmaceutiche contenenti una calcitonina
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
JPH05246846A (ja) 1992-03-03 1993-09-24 Taiyo Kagaku Co Ltd 蛋白質の消化促進組成物
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
WO1996040192A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU1808897A (en) 1995-12-13 1997-07-03 Dullatur Limited A calcitonin preparation
CA2198966C (en) * 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5912240A (en) * 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
AU1071200A (en) * 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
ATE234017T1 (de) 2000-03-31 2003-03-15 Council Scient Ind Res Getreidenahrungsmittel mit hohem nährwert
AU2001254621A1 (en) * 2000-05-05 2001-11-20 K.U. Leuven R And D Critical illness neuropathy
CA2422580C (en) 2000-09-18 2011-05-17 Rpg Life Sciences Limited Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities
GB2368792A (en) * 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
IL162294A0 (en) * 2001-12-19 2005-11-20 Alza Corp Formulation & dosage form for the controlled delivery of therapeutic agents
GB0206792D0 (en) * 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules

Also Published As

Publication number Publication date
PT1613355E (pt) 2012-12-26
KR20060021293A (ko) 2006-03-07
SI1613355T1 (sl) 2013-01-31
CN100506280C (zh) 2009-07-01
AU2004229217A1 (en) 2004-10-28
JP2006523663A (ja) 2006-10-19
GB0308734D0 (en) 2003-05-21
US20060122097A1 (en) 2006-06-08
CY1113461T1 (el) 2016-06-22
CA2522146A1 (en) 2005-10-13
BRPI0409413B1 (pt) 2017-05-02
JP5047611B2 (ja) 2012-10-10
RU2005135428A (ru) 2006-06-10
CN1805759A (zh) 2006-07-19
PL1613355T3 (pl) 2013-09-30
RU2349344C2 (ru) 2009-03-20
HK1078277A1 (en) 2006-03-10
ZA200508344B (en) 2007-12-27
CA2522146C (en) 2012-06-12
AU2004229217B2 (en) 2010-03-25
KR101135784B1 (ko) 2012-04-16
NZ543172A (en) 2009-05-31
BRPI0409413B8 (pt) 2021-05-25
US8314058B2 (en) 2012-11-20
EP1613355B1 (en) 2012-09-19
WO2004091667A1 (en) 2004-10-28
EP1613355A1 (en) 2006-01-11
ES2394640T3 (es) 2013-02-04
DK1613355T3 (da) 2013-01-02

Similar Documents

Publication Publication Date Title
BRPI0409413A (pt) composição farmacêutica, uso de um ácido ou sal biliar não conjugado, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um pacinete e para tratar um paciente que esteja sofrendo de uma condição ou doença tratável
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
EA201170969A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
BR0113400A (pt) Método para seleção de peptìdeo
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BRPI0409440A (pt) composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença
BR0109966A (pt) Combinação de compostos orgânicos
BRPI0408256A (pt) composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR0206641A (pt) Uso de compostos de azetidinona substituìda para o tratamento de sitosterolemia
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
WO2006039231A3 (en) Topical formulations for the treatment of depression with s adenosyl methionine
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0015939A (pt) Sistemas terapêuticos transdérmicos com estabilidade aperfeiçoada e um processo para a sua preparação
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
BR9909872A (pt) uso de dexmedetomidina para uma unidade de sedação de proteção intensiva
BR0110208A (pt) Composições e terapias para distúrbios associados com hiperlipidemia
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
AR043117A1 (es) Tratamiento de enfermedades bacterianas de los organos respiratorios

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AXCESS LIMITED (GB)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090000996/RJ DE 06/01/2009.

B25G Requested change of headquarter approved

Owner name: AXCESS LIMITED (GB)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090063629/RJ DE 29/06/2009.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2770 DE 06-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.